Keywordsmetformin; mammalian target of rapamycin; epithelial-mesenchymal transition; PKM2; sulfiredoxin; cervical cancer; metastasis; Wnt/β-catenin signaling; bladder cancer; chemokine (C-C motif) ligand 2; epithelial-mesenchymal transition; signal transducer and activator of transcription 3; tanshinone IIA; colorectal cancer; KRAS; ASCT2; SLC1A5; PGK1; MYC; hepatocellular carcinoma; metastasis; Warburg effect; breast cancer; co-culture; osteoclasts; mesenchymal stromal cells; non-canonical osteoclastogenesis; breast cancer; invasion; metastasis; ruthenium; CLDN6; DNMT1; methylation; SMAD2; breast cancer; radiotherapy; radioresistance; CSCs; EMT; metastasis; LncRNAs; breast cancer; metastasis; therapy resistance; ALDH1A1; ALDH1A3; abnormal tumor vasculature; anti-angiogenesis; cancer-associated fibroblasts; endothelial cell–tumor cell interaction; targeted tumor therapy; tumor neovascularization; tumor metabolism; tumor stroma; tumor vessel disruption; vasculogenic mimicry; melanoma; BRAF; Melphalan; pelvic perfusion; hypoxia; stopflow; prostate cancer; fluorescence imaging; bioluminescence imaging; fluorescence tomography; enhanced permeability and retention (EPR) effect; LipImageTM; breast cancer metastasis; cytochrome P450; 20-HETE; cyprodinil (CYP); 3,3′-diindolylmethane (DIM); epithelial-mesenchymal transition (EMT); metastasis; n/a
